For research use only. Not for therapeutic Use.
Nafenopin（Cat No.:I008225） is a peroxisome proliferator compound that has been used experimentally to induce liver tumors. Although it has been explored as an antihyperlipoproteinemic agent for managing elevated lipid levels, it is primarily recognized as a hypolipidemic agent. Nafenopin exerts its hypolipidemic effects by altering lipid metabolism and promoting the breakdown of fatty acids in the liver.
| CAS Number | 3771-19-5 |
| Synonyms | Nafenopene; Nafenopino; Nafenopinum; Nafenoic Acid; Melipan; Nafenopin;2-methyl-2-(4-(1,2,3,4-tetrahydronaphthalen-1-yl)phenoxy)propanoic acid |
| Molecular Formula | C20H22O3 |
| Purity | ≥95% |
| Solubility | Soluble in DMSO, not in water |
| Storage | Room Temperature |
| IUPAC Name | 2-methyl-2-[4-(1,2,3,4-tetrahydronaphthalen-1-yl)phenoxy]propanoic acid |
| InChI | InChI=1S/C20H22O3/c1-20(2,19(21)22)23-16-12-10-15(11-13-16)18-9-5-7-14-6-3-4-8-17(14)18/h3-4,6,8,10-13,18H,5,7,9H2,1-2H3,(H,21,22) |
| InChIKey | XJGBDJOMWKAZJS-UHFFFAOYSA-N |
| SMILES | CC(C)(C(=O)O)OC1=CC=C(C=C1)C2CCCC3=CC=CC=C23 |
| Reference | </br>1:The hypolipidemic drug metabolites nafenopin-CoA and ciprofibroyl-CoA are competitive P2Y1 receptor antagonists. Coddou C, Loyola G, Boyer JL, Bronfman M, Huidobro-Toro JP.FEBS Lett. 2003 Feb 11;536(1-3):145-50. PMID: 12586354 Free Article</br>2:Nafenopin-, ciprofibroyl-, and palmitoyl-CoA conjugation in vitro: kinetic and molecular characterization of marmoset liver microsomes and expressed MLCL1. Drogemuller CJ, Nunthasomboon S, Knights KM.Arch Biochem Biophys. 2001 Dec 1;396(1):56-64. PMID: 11716462 </br>3:Role of hepatic non-parenchymal cells in the response of rat hepatocytes to the peroxisome proliferator nafenopin in vitro. Hasmall SC, West DA, Olsen K, Roberts RA.Carcinogenesis. 2000 Dec;21(12):2159-65. PMID: 11133804 </br>4:A dominant negative form of IKK2 prevents suppression of apoptosis by the peroxisome proliferator nafenopin. Cosulich SC, James NH, Needham MR, Newham PP, Bundell KR, Roberts RA.Carcinogenesis. 2000 Sep;21(9):1757-60. PMID: 10964109 </br>5:Proteomic analysis of differential protein expression in primary hepatocytes induced by EGF, tumour necrosis factor alpha or the peroxisome proliferator nafenopin. Chevalier S, Macdonald N, Tonge R, Rayner S, Rowlinson R, Shaw J, Young J, Davison M, Roberts RA.Eur J Biochem. 2000 Aug;267(15):4624-34. PMID: 10903494 Free Article</br>6:Nafenopin causes protein kinase C-mediated serine phosphorylation and loss of function of connexin 32 protein in rat hepatocytes without aberrant expression or localization. Elcock FJ, Deag E, Roberts RA, Chipman JK.Toxicol Sci. 2000 Jul;56(1):86-94. PMID: 10869456 </br>7:Tumour necrosis factor alpha (TNFalpha): role in suppression of apoptosis by the peroxisome proliferator nafenopin. Holden PR, Hasmall SC, James NH, West DR, Brindle RD, Gonzalez FJ, Peters JM, Roberts RA.Cell Mol Biol (Noisy-le-grand). 2000 Feb;46(1):29-39. PMID: 10726969 </br>8:In vitro covalent binding of nafenopin-CoA to human liver proteins. Sallustio BC, Nunthasomboon S, Drogemuller CJ, Knights KM.Toxicol Appl Pharmacol. 2000 Mar 1;163(2):176-82. PMID: 10698675 </br>9:Role for tumor necrosis factor alpha receptor 1 and interleukin-1 receptor in the suppression of mouse hepatocyte apoptosis by the peroxisome proliferator nafenopin. West DA, James NH, Cosulich SC, Holden PR, Brindle R, Rolfe M, Roberts RA.Hepatology. 1999 Dec;30(6):1417-24. PMID: 10573520 </br>10:G1-arrested FaO cells re-enter the cell cycle upon stimulation with the rodent non-genotoxic hepatocarcinogen nafenopin. Chevalier S, Roberts RA.Carcinogenesis. 1999 Jul;20(7):1209-13. PMID: 10383891 |
